Why Does UK Medical Cannabis Rely on Private Clinics So Much?

The conversation around medical cannabis in the UK has evolved dramatically since November 2018, when regulatory changes allowed specialist doctors to prescribe cannabis-based products for medicinal use. Yet, despite this landmark shift, NHS prescriptions for medical cannabis remain rare, and private clinics have become the main access point for patients. This blog post explores the reasons behind the heavy reliance on private prescribing, the ongoing confusion between Class and Schedule drug classifications, and the evidence gap that limits NHS provision. Along the way, we’ll naturally highlight companies like Nationwide Pharmacies who play a pivotal role in private medical cannabis supply.

Understanding the Legal Framework: Class vs Schedule

Before diving into why private clinics dominate medical cannabis access, it’s crucial to clarify two often-misused terms in UK drug law: Class and Schedule.

• Class refers to the classification of drugs under the Misuse of Drugs Act 1971 based on potential harm and penalty severity. Cannabis is a Class B drug, making it illegal to possess or supply without authority.
• Schedule refers to the classification under the Misuse of Drugs Regulations 2001 that governs medicinal use, production, and supply of controlled substances. Medical cannabis can fall under Schedule 2 or Schedule 1 depending on the form and product.

This distinction is important because cannabis remains illegal under the 1971 Act’s Class B classification for recreational use, but certain cannabis-based medicinal products (CBMPs) classified under Schedule 2 can be prescribed legally under strict controls.

Takeaway: Class determines criminal penalties for recreational use, Schedule governs medical prescribing rules.

What Changed in November 2018?

November 2018 marked a watershed moment for UK medical cannabis when the Home Office rescheduled cannabis-based products for medicinal use. This allowed specialist doctors on the General Medical Council (GMC) specialist register to prescribe CBMPs legally on the NHS or privately.

• Before this, cannabis was effectively Schedule 1 — meaning no recognised medicinal value and illegal to prescribe.
• After the change, CBMPs could be prescribed under Schedule 2, similar to morphine or methadone, subject to stringent regulations.

Despite this legal opening, NHS prescriptions have remained rare, with few clinicians willing or able to prescribe. This scarcity is one key factor driving growth in private prescribing and clinics.

Takeaway: The 2018 rescheduling legalised medical prescribing but did not create broad NHS access.

Why Cannabis Remains Illegal Under the 1971 Act

Although specialist prescribing for medical cannabis is now legal, recreational cannabis possession and use remain illegal under the Misuse of Drugs Act 1971. It remains a Class B controlled drug — potentially incurring criminal penalties for unauthorised possession or supply.

On top of that, the 1971 Act places cannabis in a framework that does not easily accommodate widespread medical availability. Only specific cannabis-based products meeting strict quality and safety standards can be licensed as medicines. Many cannabis "strains" or flower remain Schedule 1 and illegal to prescribe.

The continued classification under the 1971 Act means:

1. Specialist doctors can only prescribe authorised CBMPs, not raw cannabis flower or other forms.
2. There is tight Home Office oversight with complex licensing and storage requirements for clinics and pharmacies handling medical cannabis.
3. The NHS is cautious due to the legal and regulatory complexities, and limited evidence of consistent clinical benefits from large trials.

Takeaway: Cannabis’s ongoing illegal classification for recreational use restricts broad medical prescribing under NHS.

Specialist-Only Prescribing: A Barrier to NHS Access

Ever notice how under current regulations, only doctors on the gmc’s specialist register in certain fields can initiate medical cannabis prescriptions — commonly pain specialists, neurologists, or palliative care consultants. GPs https://www.tntmagazine.com/leisure-entertainment/leisure/why-is-cannabis-still-illegal-in-the-uk-the-history-behind-medical-cannabis-law/ are not authorised to prescribe CBMPs.

This specialist-only prescribing rule aims to ensure responsible use, given the drug’s complex pharmacology and the limited clinical trial data. However, it constrains patient access for several reasons:

• There are few specialists with expertise or willingness to prescribe CBMPs on the NHS.
• NHS clinicians may face institutional pressures or lack of clear guidelines, due to the evidence gap and high costs of approved products.
• Waiting lists and referral pathways to appropriate specialists can be long, resulting in delays for patients.

That means patients seeking medical cannabis often turn to private clinics where specialists have more freedom to prescribe and offer faster appointments. These clinics, such as those working with Nationwide Pharmacies, have become instrumental in meeting patient demand.

Takeaway: Specialist-only prescribing limits NHS availability, pushing patients toward private providers.

The Evidence Gap: Why NHS Prescriptions Remain Rare

The NHS’s cautious approach also stems from the significant evidence gap around medical cannabis. While patient testimonials and some clinical studies report benefits for conditions like chronic pain, epilepsy, and multiple sclerosis, the overall quality and quantity of robust randomised controlled trials (RCTs) remain limited.

• This sparse evidence challenges NHS decision-makers tasked with allocating finite resources.
• CBMPs tend to be expensive branded products that must demonstrate cost-effectiveness versus existing therapies.
• Concerns remain about potential side effects, long-term safety, and standardisation of products.

Private clinics are less constrained by NHS cost-effectiveness thresholds and access criteria, enabling faster adoption of CBMP prescriptions based on clinician judgment and patient need.

Takeaway: NHS hesitancy over medical cannabis reflects the current evidence gap and cost concerns.

Why Private Prescribing is Growing

Given all these factors, private prescribing has expanded considerably in the UK medical cannabis market. Here’s why private clinics and companies like Nationwide Pharmacies have become crucial:

1. Accessibility: Private clinics offer more streamlined patient referral and consultation processes, with shorter wait times than NHS specialist referrals.
2. Choice of Products: Private providers can source a wider range of licensed CBMPs, including oils and capsules tailored to patient preferences.
3. Confidentiality and Personalised Care: Patients often appreciate the privacy and dedicated support offered by specialised private services.
4. Education and Advocacy: Private clinics often invest in educating patients on dosing and managing side effects — areas where NHS resources can be limited.
5. Supply Chain Expertise: Companies such as Nationwide Pharmacies facilitate regulated and timely delivery of medical cannabis, ensuring quality-controlled products to patients.

However, private prescribing comes at a cost, making medical cannabis inaccessible for many without significant personal expense.

Takeaway: Private clinics fill NHS gaps by offering faster, broader, and more personalised access to medical cannabis.

Conclusion

While the legalisation of medical cannabis prescribing in 2018 was a major step forward, it did not democratise access on the NHS. Complex drug scheduling, the continued illegal status of recreational cannabis, specialist-only prescribing restrictions, and the evidence gap have all limited NHS prescriptions.

So private clinics and pharmacies like Nationwide Pharmacies have become vital in supplying medical cannabis to UK patients. They address long NHS wait times and restrictive prescribing rules — at a notable cost to patients.

Ongoing research, clearer NHS guidelines, and evolving drug classifications may eventually expand NHS access. Until then, private prescribing growth remains the main pathway for many seeking relief through medical cannabis.

Summary takeaway: UK medical cannabis relies heavily on private clinics due to restrictive drug scheduling, specialist-only NHS prescribing, limited clinical evidence, and the NHS’s cautious approach — with companies like Nationwide Pharmacies bridging critical access gaps in the private sector.